Living to 100 is an extraordinary outcome, but it does not describe a single kind of health. A person can postpone cardiovascular disease, remain independent after a diagnosis, or survive for years while needing substantial support. Those are different achievements, and longevity research becomes more useful when it measures each one.
A review published October 26 in Nature Reviews Cardiology brings that distinction into focus. Pedro Carrera-Bastos and colleagues examine cardiovascular resilience in centenarians, describing delayed disease alongside adaptations and the selection inherent in studying exceptional survivors. Their synthesis is a timely reason to revisit what the hundredth birthday can, and cannot, tell researchers about healthspan.
The TENS Magazine analysis is that centenarian research needs two linked timelines: when disease appears and when daily function changes. Neither timeline can substitute for the other. Comparing the new review with earlier longitudinal studies also reveals a second distinction: illness can begin later yet occupy more total years of a longer life.
A resilient heart can still show aging
The new review describes age-related changes in centenarians’ hearts and blood vessels, including greater stiffness. It also notes that cardiovascular and metabolic conditions remain common, even though their onset is often later than in people aged 80–100. This is a review of existing evidence, not a new trial demonstrating that a particular intervention extends life.
For TENS, that changes the question a useful biomarker should answer. A measurement that distinguishes a younger heart from an older one may not explain why an older person continues functioning. Research into resilience has to connect biological changes with consequences: symptoms, clinical events and the ability to manage everyday life. Otherwise, a striking molecular result can leave the central human outcome unresolved.
Follow the years before 100
An earlier U.S. study by Jennifer Ailshire and colleagues used the Health and Retirement Study to compare 96 people who reached 100 with 1,045 participants who died before that birthday. It followed disease, disability and cognition over time rather than relying only on a snapshot of people already aged 100.
Its findings resist a single description of successful aging. About 23 percent of centenarians reached 100 without the major chronic diseases assessed, 18 percent without disability and 55 percent without cognitive impairment. These are separate measures, not three estimates of the same outcome. The study relied on reported diagnoses and functioning, did not cover every disease, and lacked precise onset dates and detailed information about disease severity.
TENS reads those distinctions as a requirement for clearer research reporting. A headline about disease-free survival should not quietly become a claim about independent living. Equally, preserved independence should not be interpreted as evidence that underlying cardiovascular changes are absent. Both outcomes deserve attention because they answer different questions for patients, families and care systems.
Later illness can still mean more years of care
A Swedish longitudinal analysis led by Davide Vetrano offers another perspective. The researchers compared 222 centenarians with 3,573 shorter-lived participants, using data from two Stockholm aging studies. Multimorbidity, disability and cognitive impairment appeared four to nine years later among those who became centenarians.
Yet the centenarians spent more years with these conditions. The reported time with multimorbidity was 9.4 years versus 6.8 among shorter-lived peers; time with disability was 4.3 versus 3.1 years. The analysis therefore separates postponement from the total duration of need. Its observational, geographically specific findings do not establish what would happen if an intervention made another population live longer.
That distinction matters for healthspan infrastructure. TENS would judge a proposed improvement on both the additional years of independence and the support required across the remaining years. Later onset is valuable, but it does not automatically reduce demand for accessible housing, assistance with daily activities or coordinated care. Research summaries should show the whole trajectory before translating a longevity result into a claim about future service needs.
What the comparison can support
The studies cannot be combined into one universal centenarian score. Their populations, measurement methods and definitions differ. Nor does comparing exceptional survivors with shorter-lived peers identify a transferable cause of longevity: reaching 100 already selects people through many decades of differing circumstances and health risks.
The practical research agenda emerging from this comparison is more specific than finding a youthful biological signature. TENS proposes reporting disease onset, functional change and years lived with support needs together, while making recruitment and measurement limits visible. This is an editorial standard for evaluating evidence, not a validated clinical tool.
Yesterday’s review strengthens the case for investigating cardiovascular resilience. The longitudinal evidence keeps the ambition grounded in lived outcomes. No treatment or supplement recommendation follows from these findings, and no lifespan or healthspan benefit from an intervention is demonstrated here. The opportunity is to learn how long lives unfold, then test whether the mechanisms identified can improve function as well as survival.
TENS Magazine conceptual illustration